A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer

Lung Cancer

Volumn 76, Issue 3, 2012, Pages 380-386

  Gao, Guanghui ^a   Chu, Haiqing ^a   Zhao, Lan ^a   Gui, Tao ^a   Xu, Qinghua ^a   Shi, Jianping ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Wuxi No 3 People's Hospital   (China)

Author keywords

Carcinoma; Meta analysis; Non small cell lung; Paclitaxel; Weekly schedule

Indexed keywords

CARBOPLATIN; CETUXIMAB; GEMCITABINE; PACLITAXEL;

ADVANCED CANCER; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; FEBRILE NEUTROPENIA; FEVER; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; META ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME;

EID: 84860516175     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.12.001     Document Type: Article

References (26)

1. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236.
2. Smith B.D., Smith G.L., Hurria A., Hortobagyi G.N., Buchholz T.A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009, 27:2758-2765.
3. Novello S., Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1. Early-stage disease. Oncology (Williston Park) 2003, 17:357-364.
4. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
5. Alberti W. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311:899-909.
6. D'Addario G., Pintilie M., Leighl N.B., Feld R., Cerny T., Shepherd F.A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005, 23:2926-2936.
7. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
8. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
9. Scagliotti G.V., De Marinis F., Rinaldi M., Crinò L., Gridelli C., Ricci S., et al. Italian Lung Cancer Project: phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
10. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005, 47:69-80.
11. Grossi F., Aita M., Defferrari C., Rosetti F., Brianti A., Fasola G., et al. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 2009, 14:497-510.
12. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
13. Kubota K., Kawahara M., Ogawara M., Nishiwaki Y., Komuta K., Minato K., et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 2008, 9:1135-1142.
14. Inoue A., Usui K., Ishimoto O., Matsubara N., Tanaka M., Kanbe M., et al. A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer 2006, 52:83-87.
15. Socinski M.A., Ivanova A., Bakri K., Wall J., Baggstrom M.Q., Hensing T.A., et al. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 2006, 17:104-109.
16. Belani C.P., Dakhil S., Waterhouse D.M., Desch C.E., Rooney D.K., Clark R.H., et al. Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Ann Oncol 2007, 18:110-115.
17. Belani C.P., Ramalingam S., Perry M.C., LaRocca R.V., Rinaldi D., Gable P.S., et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008, 26:468-473.
18. Socinski M.A., Saleh M.N., Trent D.F., Dobbs T.W., Zehngebot L.M., Levine M.A., et al. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol 2009, 20:1068-1073.
19. Sakakibara T., Inoue A., Sugawara S., Maemondo M., Ishida T., Usui K., et al. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Ann Oncol 2010, 21:795-799.
20. Dickersin K., Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994, 309:1286-1291.
21. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 1996, 17:1-12.
22. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
23. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
24. Owonikoko T.K., Ragin C.C., Belani C.P., Oton A.B., Gooding W.E., Taioli E., et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007, 25:5570-5577.
25. McLean A.J., Le Couteur D.G. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004, 56:163-184.
26. Ramalingam S., Perry M.C., La Rocca R.V., Rinaldi D., Gable P.S., Tester W.J., et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 2008, 113:542-546.